The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 26, 2020
Filed:
Nov. 13, 2018
Applicant:
Pfizer Inc., New York, NY (US);
Inventors:
Kevin Richard Back, Sandwich, GB;
Michael Cram, Sandwich, GB;
Aidan James Harper, Sandwich, GB;
W. James Huang, New York, NY (US);
Jonathan Richard Lillis, Sandwich, GB;
Timothy Michael Lukas, Sandwich, GB;
Sumit Luthra, New York, NY (US);
Assignee:
Pfizer Inc., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/12 (2006.01); C07D 401/12 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 31/5377 (2006.01); A61K 47/02 (2006.01);
U.S. Cl.
CPC ...
A61K 47/12 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/5377 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01); C07D 401/12 (2013.01); C07B 2200/13 (2013.01);
Abstract
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.